Nicotinic acetylcholine receptor subunit alpha-4 (CHRNA4)

The Nicotinic acetylcholine receptor subunit alpha-4 (CHRNA4) is a core component of the most abundant high-affinity nicotinic receptor subtype, the heteromeric alpha-4-beta-2 (α4β2) receptor, within the human central nervous system (UniProt: P43681). These receptors function as ligand-gated cation channels that mediate fast excitatory neurotransmission and modulate the release of several key neurotransmitters, including dopamine, GABA, and glutamate (NCBI Gene: 1137). CHRNA4 is intrinsically involved in the brain's reward system, making it the primary target for nicotine and smoking cessation agents like varenicline (StatPearls: NBK535346). Mutations in the CHRNA4 gene are specifically linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy, emphasizing its role in maintaining the balance of cortical excitability (PubMed: 7566106). Furthermore, a decline in the expression of this subunit is frequently observed in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, where it is associated with cognitive decline (PubMed: 11502450). Therapeutic strategies often focus on selective partial agonism to alleviate addiction symptoms while avoiding full activation and subsequent receptor desensitization (PubMed: 17015830).

Other names

Cholinergic receptor nicotinic alpha 4 subunitNeuronal acetylcholine receptor subunit alpha-4nAChR alpha-4NACHRA4BFNCEBNEBN1

Drugs targeting this subunit typically act as agonists or partial agonists that bind to the orthosteric site at the interface of the alpha-4 and beta-2 subunits, inducing a conformational change that opens the central ion pore to allow cation influx (sodium, calcium, and potassium). This leads to neuronal depolarization and the subsequent release of neurotransmitters such as dopamine, which modulates reward and cognitive pathways (PubMed: 17015830). Some compounds also act as positive allosteric modulators (PAMs) to enhance endogenous cholinergic signaling (PubMed: 22444311).